Eric Dean Cline

Title: Eric Dean Cline: Innovator in Antidiabetic Compounds

Introduction

Eric Dean Cline is a notable inventor based in Princeton, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating Type 2 diabetes mellitus.

Latest Patents

Cline holds a patent for "Antidiabetic bicyclic compounds." This patent describes bicyclic compounds containing a phenyl or pyridyl ring fused to a cycloalkyl or heterocyclic ring. These compounds are attached to a 5-membered heterocyclic ring and include pharmaceutically acceptable salts and prodrugs. They act as agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, especially in treating Type 2 diabetes and associated conditions such as obesity and lipid disorders, including mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. Cline has 1 patent to his name.

Career Highlights

Eric Dean Cline is currently employed at Merck Sharp & Dohme Corp., a leading global healthcare company. His work focuses on innovative solutions in the pharmaceutical industry, contributing to advancements in diabetes treatment.

Collaborations

Cline has collaborated with notable colleagues, including Min Ge and Lihu Yang, to further his research and development efforts in the field of antidiabetic compounds.

Conclusion

Eric Dean Cline is a prominent inventor whose work in antidiabetic compounds has the potential to significantly impact the treatment of Type 2 diabetes and related health issues. His contributions to the pharmaceutical industry are noteworthy and continue to advance medical science.